Multimodal treatment in oligometastatic gastric cancer.

World J Gastrointest Oncol

Division of Digestive Surgery, Geneva University Hospital and Faculty of Medicine, Geneva 1205, Genève, Switzerland.

Published: February 2022

Gastric cancer is generally diagnosed at an advanced stage, especially in countries without screening programs. Previously, the metastatic stage was synonymous with palliative management, and surgical indications were only for symptomatic relief. However, this therapeutic option is associated with poor prognosis. A subgroup of patients with limited metastatic disease could benefit from intensive treatment. A combination of chemotherapy, immunotherapy, and targeted therapy could help either maintain a resectable state for oligometastatic disease or diminish the metastasis size to obtain a complete resection configuration. This latter strategy is known as conversion therapy and has growing evidence with favorable outcomes. Oncosurgical approach of metastatic disease could prolong survival in selected patients. The challenge for the surgeon and oncologist is to identify these specific patients to offer the best multimodal management. We review in this article the actual evidence for the treatment of oligometastatic gastric cancer with curative intent.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919006PMC
http://dx.doi.org/10.4251/wjgo.v14.i2.434DOI Listing

Publication Analysis

Top Keywords

gastric cancer
12
treatment oligometastatic
8
oligometastatic gastric
8
metastatic disease
8
multimodal treatment
4
cancer gastric
4
cancer generally
4
generally diagnosed
4
diagnosed advanced
4
advanced stage
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!